Key highlights
- Cook Medical led a Series D funding round for Zenflow, reinforcing Cook’s long-term commitment to prostate health innovation.
- Cook Medical will become the sole distributor of the Zenflow Spring® Implant and Delivery System, a minimally invasive, office-based treatment for benign prostatic hyperplasia (BPH).
- The Zenflow Spring expands Cook Medical’s portfolio of prostate health products.
The Zenflow Spring® Implant and Delivery System in anatomy
Bloomington, Ind. — Cook Medical led an oversubscribed $52 million Series D financing round for Zenflow, a medical device company. Additionally, Cook Medical signed an agreement to become the sole U.S. distributor of the Zenflow Spring® Implant and Delivery System, the company’s product.
The Zenflow Spring is a minimally invasive implant designed to provide lasting relief for patients suffering from lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). This innovative device is the latest addition to Cook Medical’s pipeline of prostate health products.
About the Zenflow Spring
The Zenflow Spring is a novel, nitinol-based implant inserted into the urethra. The device opens a new category of treatment called first-line interventional therapy (FIT), giving physicians a device-based option they can offer instead of drug therapy, or ahead of Minimally Invasive Surgical Therapies (MISTs). The device is designed to provide safe, effective, and durable relief from obstructive lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH) while preserving sexual function — a key differentiator in the BPH treatment landscape.
Patients may receive this device in a simple, office-based procedure without the need for general anesthesia, incisions or removal of prostate tissue, virtually eliminating the need for post-operative catheterization. Importantly, the procedure can be fully reversed if ever desired by simply removing the implant.
A Deepening Partnership
Cook Medical first invested in Zenflow as part of an earlier funding round, recognizing the transformative potential of the Zenflow Spring technology to address a significant unmet clinical need. BPH affects millions of patients worldwide, and the Zenflow Spring offers a compelling, office-based alternative to more invasive surgical procedures.
Shreya Mehta, Chief Executive Officer of Zenflow, said, “Cook Medical’s deep relationships within urology and proven commercialization capabilities make them the ideal partner to help bring the benefits of the Zenflow Spring to patients across the country. We are thrilled to close this round of financing, demonstrate our commercial potential, and help physicians treat many more patients.”
About Benign Prostatic Hyperplasia
The prostate is a small gland that helps make semen and surrounds the tube that carries urine out of the body called the urethra. The prostate can grow larger as the patient ages, which is called benign prostatic hyperplasia (BPH) or enlarged prostate. This growth can press on the urethra, making it harder to urinate and leading to symptoms that disrupt quality of life, including difficulty starting or fully emptying the bladder, a weak or interrupted stream, increased frequency and urgency, nighttime urination, and discomfort. About 50% of men between the ages of 51 and 60 have BPH, and that number jumps to 70% among men aged 60 to 69 and around 80% of men over 70 years of age.
Cook Medical’s prostate health portfolio is dedicated to treating BPH and many other prostate pathologies. The exclusive distribution agreement in the U.S. positions Cook Medical as a key commercial partner for Zenflow, leveraging Cook Medical’s sales infrastructure, deep relationships with urologists, and decades of expertise in minimally invasive medical devices. The Zenflow Spring complements Cook Medical’s existing portfolio of urology and prostate health products, creating a comprehensive offering for healthcare providers treating BPH.
Quotes
“Our initial investment in Zenflow reflected our confidence in both the technology and the team,” said DJ Sirota, senior vice president of Cook Medical’s MedSurg division. “Today, we are proud to deepen that commitment with a substantial Series D investment and to take on the role of sole U.S. distributor for the Zenflow Spring. This is a significant addition to Cook Medical’s prostate health portfolio and aligns perfectly with our mission to deliver innovative, minimally invasive solutions that improve patient outcomes.”
“BPH is one of the most prevalent conditions affecting men’s quality of life, and yet many patients remain undertreated or dissatisfied with existing options,” said Johan Lowinger, director of product management for Cook Medical’s Urology specialty. “The Zenflow Spring represents exactly the kind of breakthrough we look for — a simple, effective, office-based solution that puts patients first. We are excited to bring this technology to urologists and their patients through our distribution network.”
FAQs
What is the Zenflow Spring and what does it treat?
The Zenflow Spring is a minimally invasive, nitinol-based implant designed to treat the symptoms of benign prostatic hyperplasia (BPH), a common condition in which an enlarged prostate causes urinary symptoms such as frequent urination, weak urine flow, and incomplete bladder emptying. The procedure may be performed in an office setting without general anesthesia, incisions or removal of prostate tissue. It is also fully reversible, if needed.
What is Cook Medical’s role in this agreement?
Cook Medical will serve as the sole distributor of the Zenflow Spring in the United States, leveraging its established relationships with urologists and its commercial infrastructure to bring the device to healthcare providers and their patients worldwide.
When will the Zenflow Spring be available through Cook Medical?
Details regarding commercial availability and market rollout timelines will be communicated in due course. Please contact your Cook Medical representative or visit www.cookmedical.com for updates.
How does this investment fit into Cook Medical’s broader strategy?
The Zenflow Spring is a strategic addition to Cook Medical’s growing portfolio of prostate health and urology products. Cook Medical is committed to developing and distributing minimally invasive solutions that reduce the burden of surgical intervention and improve patient outcomes across a range of conditions.
About Cook Medical
At Cook Medical, we are passionate about making unique, quality medical devices and connecting with people to improve lives. Founded on inventing, manufacturing, and delivering medical devices, we provide healthcare professionals with the tools they need to help their patients return to living.
Our commitment to innovation involves bringing new products to market and keeping existing products relevant to a changing healthcare landscape. We believe in using our business to help people and communities thrive by creating inclusive, supportive, and healthy environments.
We are proud of our history of innovative firsts and the impact we have on patients and communities. With headquarters in Bloomington, Indiana, and manufacturing facilities and offices in various global locations, we challenge ourselves to maintain a global perspective while focusing on local impact.
Follow Cook Medical at CookMedical.com and on LinkedIn.
About Zenflow
Zenflow is a medical device company developing innovative therapies for the treatment of benign prostatic hyperplasia (BPH). The company’s flagship product, the Zenflow Spring System, is designed to provide durable symptom relief through a minimally invasive approach that preserves future treatment options and supports physician workflow efficiency. For more information, visit www.zenflow.com, and follow Zenflow on LinkedIn and X for the latest updates.